BeOne Medicines AG ONC
392.82 USD -6.88 (-1.72%)
As ofNov 20, 2026, 2:32 PM EST
385.00 Day range 399.76
260.27 52-week range 424.00
- YTD
- +29.30%
- 1 year
- +12.46%
News
benzinga.com JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $460 JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $445 to $460.
benzinga.com If You Invested $100 In BeOne Medicines Stock 10 Years Ago, You Would Have This Much Today BeOne Medicines (NASDAQ:ONC) has outperformed the market over the past 10 years by 16.62% on an annualized basis producing an average annual return of 29.37%. Currently, BeOne Medicines has a market…benzinga.com BeOne Medicines Partners With CLL Society To Expand Support For Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma Resources Through this new three-year Visionary Partnership, BeOne is expanding its support for CLL Society to $3 million, advancing several initiatives that reflect the organization’s evolving approach to…
businesswire.com CLL Society and BeOne Medicines Announce Expanded Partnership to Advance Education and Support Across the CLL/SLL Community NASHVILLE, Tenn. & SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--CLL Society, a leading authority for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients, and…benzinga.com Morgan Stanley Maintains Overweight on BeOne Medicines, Raises Price Target to $476 Morgan Stanley analyst Sean Laaman maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $465 to $476.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million. Nkarta (NASDAQ:NKTX) stock…benzinga.com RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $465 RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and raises the price target from $459 to $465.
benzinga.com Truist Securities Reiterates Buy on BeOne Medicines, Raises Price Target to $448 Truist Securities analyst Gregory Renza reiterates BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $448.
benzinga.com Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $446 Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $415 to $446.
benzinga.com Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $463 Citizens analyst Reni J. Benjamin maintains BeOne Medicines (NASDAQ:ONC) with a Market Outperform and raises the price target from $405 to $463.
benzinga.com Wells Fargo Maintains Overweight on BeOne Medicines, Raises Price Target to $435 Wells Fargo analyst Yanan Zhu maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $400 to $435.
benzinga.com BeOne Medicines Raises FY2026 Sales Guidance from $6.600B-$6.800B to $6.900B-$7.000B vs $6.763B Est BeOne Medicines (NASDAQ:ONC) raises FY2026 sales outlook from $6.600 billion-$6.800 billion to $6.900 billion-$7.000 billion vs $6.763 billion estimate.
benzinga.com BeiGene Q3 Adj. EPS $4.59 Beats $1.97 Estimate, Sales $1.890B Beat $1.758B Estimate BeiGene (NASDAQ:ONC) reported quarterly earnings of $4.59 per share which beat the analyst consensus estimate of $1.97 by 132.99 percent. This is a 73.21 percent increase over earnings of $2.65 per…
benzinga.com If You Invested $100 In BeOne Medicines Stock 10 Years Ago, You Would Have This Much Today BeOne Medicines (NASDAQ:ONC) has outperformed the market over the past 10 years by 14.31% on an annualized basis producing an average annual return of 28.04%. Currently, BeOne Medicines has a market…benzinga.com BeOne Medicines Announces Its Data From Phase 3 HERIZON-GEA-01 Study Confirms Benefits Of TEVIMBRA + ZIIHERA To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis…
